Nanobiotix Shares Climb 4.71% at Close, Driven by Remarkable Momentum
At the close on Thursday, December 4, 2024, Nanobiotix's stock recorded a rise of 4.71%, reaching 18.66 euros from 17.82 euros the previous day. This increase is part of an exceptional trend that has seen the French biotech's stock value almost multiply by seven over the year. Trading volumes remained modest with only 0.5% of the capital traded.
Continued Remarkable Surge
Nanobiotix's stock continues its remarkable surge that began several weeks ago. Over the week, the performance reached 9.38%, but it is over three months that the increase becomes spectacular with a gain of 153.2%. Over a year, the stock shows an extraordinary performance of 589.6%, while the CAC 40 has only increased by 11.94% over the same period. This dynamic occurs in a context where the 50-day moving average is at 18.32 euros, a level now surpassed by the current price, while the 200-day moving average remains significantly lower at 8.16 euros. The stock is currently trading between a technical support at 13.36 euros and a resistance at 19.56 euros, thus gradually approaching this ceiling.
Technical Analysis Insights
Technical analysis reveals a particular configuration for Nanobiotix. The RSI (Relative Strength Index) is at 50, a neutral level that indicates neither overbought nor oversold conditions, despite the recent impressive performance. This indicator suggests that the stock might maintain its potential for progression without being technically overstretched. The Bollinger Bands frame the price between 16.74 euros for the lower bound and 19.39 euros for the upper bound. The stock is thus trading in the upper part of this channel, confirming the buying pressure observed in recent weeks. The CMF (Chaikin Money Flow) at 0.10 indicates a slightly positive capital flow, consistent with the ongoing upward trend. The volatility of the stock remains high at 21.52% over a month, reflecting the magnitude of price movements. The negative beta of -0.61 highlights the stock's decoupling from the Paris market, with the CAC 40 having modestly increased by 0.43% during the session. This statistical independence is explained by the speculative profile of this biotechnological value in advanced clinical phase.
Beyond Immediate Stock Movements
Beyond immediate stock movements, Nanobiotix is gearing up to cross an important communication milestone. The company announced in mid-December the holding of a virtual event on December 19, 2024, titled 'Accelerating the Future of Nanotherapeutics', during which it will unveil its vision for its new nanotherapeutic platform Curadigm. This platform, distinct from its flagship program NBTXR3 developed with Johnson & Johnson, aims to enhance the bioavailability of drugs administered intravenously. Financially, the group had 49.7 million euros in cash as of December 31, 2024, providing visibility until mid-2026 according to its latest results published in early April 2025. The stock continues to attract investor attention in a context where expectations are focused on clinical data expected in 2025 for several therapeutic indications, including pancreatic and lung cancer.
